nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Irinotecan—colon cancer	0.0884	0.297	CbGbCtD
Cladribine—ABCG2—Fluorouracil—colon cancer	0.0848	0.285	CbGbCtD
Cladribine—ABCG2—Vincristine—colon cancer	0.0772	0.26	CbGbCtD
Cladribine—ABCG2—Methotrexate—colon cancer	0.0468	0.157	CbGbCtD
Cladribine—POLE4—embryo—colon cancer	0.011	0.0568	CbGeAlD
Cladribine—POLE2—embryo—colon cancer	0.00959	0.0496	CbGeAlD
Cladribine—POLE4—renal system—colon cancer	0.00831	0.043	CbGeAlD
Cladribine—POLE2—bone marrow—colon cancer	0.00549	0.0284	CbGeAlD
Cladribine—POLE3—embryo—colon cancer	0.00533	0.0275	CbGeAlD
Cladribine—POLE2—vagina—colon cancer	0.00526	0.0272	CbGeAlD
Cladribine—POLE4—liver—colon cancer	0.00508	0.0263	CbGeAlD
Cladribine—PNP—renal system—colon cancer	0.00459	0.0238	CbGeAlD
Cladribine—POLE2—liver—colon cancer	0.00444	0.0229	CbGeAlD
Cladribine—POLE2—Topotecan—Irinotecan—colon cancer	0.0043	0.466	CbGdCrCtD
Cladribine—RRM2B—renal system—colon cancer	0.00426	0.022	CbGeAlD
Cladribine—POLE—embryo—colon cancer	0.00406	0.021	CbGeAlD
Cladribine—POLE3—renal system—colon cancer	0.00403	0.0208	CbGeAlD
Cladribine—PNP—lymphoid tissue—colon cancer	0.00381	0.0197	CbGeAlD
Cladribine—PNP—digestive system—colon cancer	0.00377	0.0195	CbGeAlD
Cladribine—Floxuridine—TYMS—colon cancer	0.00376	0.449	CrCbGaD
Cladribine—PNP—bone marrow—colon cancer	0.00347	0.018	CbGeAlD
Cladribine—POLE2—lymph node—colon cancer	0.0034	0.0176	CbGeAlD
Cladribine—POLE3—lymphoid tissue—colon cancer	0.00335	0.0173	CbGeAlD
Cladribine—RRM2—embryo—colon cancer	0.00335	0.0173	CbGeAlD
Cladribine—POLE3—digestive system—colon cancer	0.00331	0.0171	CbGeAlD
Cladribine—NR5A1—lymphoid tissue—colon cancer	0.00324	0.0168	CbGeAlD
Cladribine—RRM2B—bone marrow—colon cancer	0.00322	0.0167	CbGeAlD
Cladribine—SLC28A3—digestive system—colon cancer	0.00309	0.016	CbGeAlD
Cladribine—RRM2B—vagina—colon cancer	0.00309	0.016	CbGeAlD
Cladribine—POLE3—bone marrow—colon cancer	0.00305	0.0158	CbGeAlD
Cladribine—Trifluridine—TYMS—colon cancer	0.00299	0.357	CrCbGaD
Cladribine—POLE3—vagina—colon cancer	0.00292	0.0151	CbGeAlD
Cladribine—SLC28A3—bone marrow—colon cancer	0.00285	0.0147	CbGeAlD
Cladribine—PNP—liver—colon cancer	0.00281	0.0145	CbGeAlD
Cladribine—RRM2B—liver—colon cancer	0.00261	0.0135	CbGeAlD
Cladribine—POLE—lymphoid tissue—colon cancer	0.00255	0.0132	CbGeAlD
Cladribine—RRM2—renal system—colon cancer	0.00253	0.0131	CbGeAlD
Cladribine—POLE—digestive system—colon cancer	0.00252	0.013	CbGeAlD
Cladribine—POLE3—liver—colon cancer	0.00246	0.0127	CbGeAlD
Cladribine—POLE—bone marrow—colon cancer	0.00232	0.012	CbGeAlD
Cladribine—POLE—vagina—colon cancer	0.00223	0.0115	CbGeAlD
Cladribine—RRM1—smooth muscle tissue—colon cancer	0.00219	0.0113	CbGeAlD
Cladribine—DCK—embryo—colon cancer	0.00216	0.0112	CbGeAlD
Cladribine—RRM1—renal system—colon cancer	0.0021	0.0109	CbGeAlD
Cladribine—RRM2—lymphoid tissue—colon cancer	0.0021	0.0109	CbGeAlD
Cladribine—RRM2—digestive system—colon cancer	0.00208	0.0107	CbGeAlD
Cladribine—POLA1—bone marrow—colon cancer	0.002	0.0104	CbGeAlD
Cladribine—RRM2B—lymph node—colon cancer	0.002	0.0103	CbGeAlD
Cladribine—SLC22A2—renal system—colon cancer	0.00197	0.0102	CbGeAlD
Cladribine—DCK—Topotecan—Irinotecan—colon cancer	0.00194	0.21	CbGdCrCtD
Cladribine—POLA1—vagina—colon cancer	0.00192	0.00993	CbGeAlD
Cladribine—RRM2—bone marrow—colon cancer	0.00191	0.0099	CbGeAlD
Cladribine—POLE3—lymph node—colon cancer	0.00189	0.00976	CbGeAlD
Cladribine—POLE—liver—colon cancer	0.00188	0.00972	CbGeAlD
Cladribine—RRM2—vagina—colon cancer	0.00183	0.00948	CbGeAlD
Cladribine—RRM1—lymphoid tissue—colon cancer	0.00175	0.00903	CbGeAlD
Cladribine—RRM1—digestive system—colon cancer	0.00173	0.00892	CbGeAlD
Cladribine—Adenosine monophosphate—SRC—colon cancer	0.00162	0.194	CrCbGaD
Cladribine—POLA1—liver—colon cancer	0.00162	0.00837	CbGeAlD
Cladribine—SLC22A2—digestive system—colon cancer	0.00162	0.00837	CbGeAlD
Cladribine—RRM1—bone marrow—colon cancer	0.00159	0.00822	CbGeAlD
Cladribine—RRM2—liver—colon cancer	0.00155	0.008	CbGeAlD
Cladribine—RRM2—Vinorelbine—Vincristine—colon cancer	0.00154	0.167	CbGdCrCtD
Cladribine—RRM1—vagina—colon cancer	0.00152	0.00788	CbGeAlD
Cladribine—POLA1—Vinblastine—Vincristine—colon cancer	0.00146	0.158	CbGdCrCtD
Cladribine—POLE—lymph node—colon cancer	0.00144	0.00745	CbGeAlD
Cladribine—SLC22A1—renal system—colon cancer	0.00139	0.00721	CbGeAlD
Cladribine—DCK—lymphoid tissue—colon cancer	0.00136	0.00702	CbGeAlD
Cladribine—DCK—digestive system—colon cancer	0.00134	0.00693	CbGeAlD
Cladribine—RRM1—liver—colon cancer	0.00129	0.00665	CbGeAlD
Cladribine—POLA1—lymph node—colon cancer	0.00124	0.00642	CbGeAlD
Cladribine—DCK—bone marrow—colon cancer	0.00124	0.00639	CbGeAlD
Cladribine—RRM2—lymph node—colon cancer	0.00119	0.00613	CbGeAlD
Cladribine—DCK—vagina—colon cancer	0.00118	0.00612	CbGeAlD
Cladribine—SLC22A1—vagina—colon cancer	0.00101	0.00522	CbGeAlD
Cladribine—DCK—liver—colon cancer	0.000998	0.00516	CbGeAlD
Cladribine—RRM1—lymph node—colon cancer	0.000986	0.0051	CbGeAlD
Cladribine—SLC22A1—liver—colon cancer	0.000851	0.0044	CbGeAlD
Cladribine—DCK—lymph node—colon cancer	0.000765	0.00396	CbGeAlD
Cladribine—ABCG2—bone marrow—colon cancer	0.000689	0.00356	CbGeAlD
Cladribine—ABCG2—vagina—colon cancer	0.00066	0.00341	CbGeAlD
Cladribine—ABCG2—liver—colon cancer	0.000557	0.00288	CbGeAlD
Cladribine—Ill-defined disorder—Irinotecan—colon cancer	0.000482	0.00162	CcSEcCtD
Cladribine—Anaemia—Irinotecan—colon cancer	0.000481	0.00162	CcSEcCtD
Cladribine—Abdominal discomfort—Capecitabine—colon cancer	0.000479	0.00161	CcSEcCtD
Cladribine—Hepatic failure—Methotrexate—colon cancer	0.000479	0.00161	CcSEcCtD
Cladribine—Pancytopenia—Capecitabine—colon cancer	0.000474	0.0016	CcSEcCtD
Cladribine—Malaise—Irinotecan—colon cancer	0.000469	0.00158	CcSEcCtD
Cladribine—Neutropenia—Capecitabine—colon cancer	0.000467	0.00157	CcSEcCtD
Cladribine—Renal failure acute—Methotrexate—colon cancer	0.000466	0.00157	CcSEcCtD
Cladribine—Upper respiratory tract infection—Capecitabine—colon cancer	0.000464	0.00156	CcSEcCtD
Cladribine—Anaemia—Fluorouracil—colon cancer	0.00046	0.00155	CcSEcCtD
Cladribine—Myalgia—Vincristine—colon cancer	0.000455	0.00153	CcSEcCtD
Cladribine—Cough—Irinotecan—colon cancer	0.000454	0.00153	CcSEcCtD
Cladribine—Pneumonia—Capecitabine—colon cancer	0.000448	0.00151	CcSEcCtD
Cladribine—Infestation NOS—Capecitabine—colon cancer	0.000445	0.0015	CcSEcCtD
Cladribine—Infestation—Capecitabine—colon cancer	0.000445	0.0015	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000442	0.00149	CcSEcCtD
Cladribine—Lethargy—Methotrexate—colon cancer	0.000439	0.00148	CcSEcCtD
Cladribine—Cerebrovascular accident—Methotrexate—colon cancer	0.000439	0.00148	CcSEcCtD
Cladribine—Renal failure—Capecitabine—colon cancer	0.000438	0.00147	CcSEcCtD
Cladribine—Discomfort—Irinotecan—colon cancer	0.000437	0.00147	CcSEcCtD
Cladribine—Oedema—Vincristine—colon cancer	0.000436	0.00147	CcSEcCtD
Cladribine—Infection—Vincristine—colon cancer	0.000433	0.00146	CcSEcCtD
Cladribine—Conjunctivitis—Capecitabine—colon cancer	0.000433	0.00146	CcSEcCtD
Cladribine—Urinary tract infection—Capecitabine—colon cancer	0.000433	0.00146	CcSEcCtD
Cladribine—Confusional state—Irinotecan—colon cancer	0.000428	0.00144	CcSEcCtD
Cladribine—Nervous system disorder—Vincristine—colon cancer	0.000427	0.00144	CcSEcCtD
Cladribine—ABCG2—lymph node—colon cancer	0.000427	0.00221	CbGeAlD
Cladribine—Thrombocytopenia—Vincristine—colon cancer	0.000427	0.00144	CcSEcCtD
Cladribine—Oedema—Irinotecan—colon cancer	0.000424	0.00143	CcSEcCtD
Cladribine—Myalgia—Fluorouracil—colon cancer	0.000424	0.00143	CcSEcCtD
Cladribine—Chest pain—Fluorouracil—colon cancer	0.000424	0.00143	CcSEcCtD
Cladribine—Infection—Irinotecan—colon cancer	0.000422	0.00142	CcSEcCtD
Cladribine—Hyperhidrosis—Vincristine—colon cancer	0.000421	0.00142	CcSEcCtD
Cladribine—Hepatobiliary disease—Capecitabine—colon cancer	0.000421	0.00142	CcSEcCtD
Cladribine—Epistaxis—Capecitabine—colon cancer	0.00042	0.00141	CcSEcCtD
Cladribine—Discomfort—Fluorouracil—colon cancer	0.000419	0.00141	CcSEcCtD
Cladribine—Nervous system disorder—Irinotecan—colon cancer	0.000416	0.0014	CcSEcCtD
Cladribine—Thrombocytopenia—Irinotecan—colon cancer	0.000416	0.0014	CcSEcCtD
Cladribine—Anorexia—Vincristine—colon cancer	0.000415	0.0014	CcSEcCtD
Cladribine—Hyperhidrosis—Irinotecan—colon cancer	0.00041	0.00138	CcSEcCtD
Cladribine—Confusional state—Fluorouracil—colon cancer	0.00041	0.00138	CcSEcCtD
Cladribine—Hypotension—Vincristine—colon cancer	0.000407	0.00137	CcSEcCtD
Cladribine—Oedema—Fluorouracil—colon cancer	0.000406	0.00137	CcSEcCtD
Cladribine—Anorexia—Irinotecan—colon cancer	0.000405	0.00136	CcSEcCtD
Cladribine—Ataxia—Methotrexate—colon cancer	0.000405	0.00136	CcSEcCtD
Cladribine—Infection—Fluorouracil—colon cancer	0.000404	0.00136	CcSEcCtD
Cladribine—Haemoglobin—Capecitabine—colon cancer	0.000402	0.00135	CcSEcCtD
Cladribine—Haemorrhage—Capecitabine—colon cancer	0.0004	0.00134	CcSEcCtD
Cladribine—Nervous system disorder—Fluorouracil—colon cancer	0.000399	0.00134	CcSEcCtD
Cladribine—Thrombocytopenia—Fluorouracil—colon cancer	0.000398	0.00134	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000397	0.00134	CcSEcCtD
Cladribine—Pharyngitis—Capecitabine—colon cancer	0.000397	0.00133	CcSEcCtD
Cladribine—Tachycardia—Fluorouracil—colon cancer	0.000397	0.00133	CcSEcCtD
Cladribine—Hypotension—Irinotecan—colon cancer	0.000397	0.00133	CcSEcCtD
Cladribine—Urinary tract disorder—Capecitabine—colon cancer	0.000395	0.00133	CcSEcCtD
Cladribine—Insomnia—Vincristine—colon cancer	0.000394	0.00133	CcSEcCtD
Cladribine—Oedema peripheral—Capecitabine—colon cancer	0.000394	0.00132	CcSEcCtD
Cladribine—Connective tissue disorder—Capecitabine—colon cancer	0.000393	0.00132	CcSEcCtD
Cladribine—Urethral disorder—Capecitabine—colon cancer	0.000392	0.00132	CcSEcCtD
Cladribine—Paraesthesia—Vincristine—colon cancer	0.000391	0.00132	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.00039	0.00201	CbGpPWpGaD
Cladribine—Anorexia—Fluorouracil—colon cancer	0.000387	0.0013	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000387	0.0013	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	0.000387	0.00199	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—TYMS—colon cancer	0.000385	0.00198	CbGpPWpGaD
Cladribine—Insomnia—Irinotecan—colon cancer	0.000384	0.00129	CcSEcCtD
Cladribine—Paraesthesia—Irinotecan—colon cancer	0.000381	0.00128	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000381	0.00196	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000381	0.00196	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.00038	0.00196	CbGpPWpGaD
Cladribine—Hypotension—Fluorouracil—colon cancer	0.00038	0.00128	CcSEcCtD
Cladribine—Decreased appetite—Vincristine—colon cancer	0.000379	0.00127	CcSEcCtD
Cladribine—Dyspnoea—Irinotecan—colon cancer	0.000378	0.00127	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—MYC—colon cancer	0.000378	0.00194	CbGpPWpGaD
Cladribine—Erythema multiforme—Capecitabine—colon cancer	0.000378	0.00127	CcSEcCtD
Cladribine—Somnolence—Irinotecan—colon cancer	0.000377	0.00127	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	0.000377	0.00194	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Vincristine—colon cancer	0.000376	0.00127	CcSEcCtD
Cladribine—Fatigue—Vincristine—colon cancer	0.000376	0.00126	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.000374	0.00193	CbGpPWpGaD
Cladribine—Eye disorder—Capecitabine—colon cancer	0.000374	0.00126	CcSEcCtD
Cladribine—Pain—Vincristine—colon cancer	0.000373	0.00125	CcSEcCtD
Cladribine—Constipation—Vincristine—colon cancer	0.000373	0.00125	CcSEcCtD
Cladribine—RRM2—E2F transcription factor network—MYC—colon cancer	0.000372	0.00191	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CHST5—colon cancer	0.000372	0.00191	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ODC1—colon cancer	0.000372	0.00191	CbGpPWpGaD
Cladribine—Cardiac disorder—Capecitabine—colon cancer	0.000371	0.00125	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00037	0.00125	CcSEcCtD
Cladribine—Decreased appetite—Irinotecan—colon cancer	0.000369	0.00124	CcSEcCtD
Cladribine—Eosinophilia—Methotrexate—colon cancer	0.000368	0.00124	CcSEcCtD
Cladribine—Insomnia—Fluorouracil—colon cancer	0.000368	0.00124	CcSEcCtD
Cladribine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000366	0.00123	CcSEcCtD
Cladribine—Fatigue—Irinotecan—colon cancer	0.000366	0.00123	CcSEcCtD
Cladribine—POLE2—S Phase—MYC—colon cancer	0.000365	0.00188	CbGpPWpGaD
Cladribine—Paraesthesia—Fluorouracil—colon cancer	0.000365	0.00123	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.000365	0.00187	CbGpPWpGaD
Cladribine—Pain—Irinotecan—colon cancer	0.000363	0.00122	CcSEcCtD
Cladribine—Constipation—Irinotecan—colon cancer	0.000363	0.00122	CcSEcCtD
Cladribine—Angiopathy—Capecitabine—colon cancer	0.000363	0.00122	CcSEcCtD
Cladribine—Dyspnoea—Fluorouracil—colon cancer	0.000362	0.00122	CcSEcCtD
Cladribine—Somnolence—Fluorouracil—colon cancer	0.000361	0.00122	CcSEcCtD
Cladribine—Immune system disorder—Capecitabine—colon cancer	0.000361	0.00121	CcSEcCtD
Cladribine—Mediastinal disorder—Capecitabine—colon cancer	0.00036	0.00121	CcSEcCtD
Cladribine—POLE2—Cell Cycle—BUB1B—colon cancer	0.000359	0.00185	CbGpPWpGaD
Cladribine—Chills—Capecitabine—colon cancer	0.000359	0.00121	CcSEcCtD
Cladribine—Arrhythmia—Capecitabine—colon cancer	0.000357	0.0012	CcSEcCtD
Cladribine—Abdominal discomfort—Methotrexate—colon cancer	0.000356	0.0012	CcSEcCtD
Cladribine—Gastrointestinal pain—Vincristine—colon cancer	0.000356	0.0012	CcSEcCtD
Cladribine—Decreased appetite—Fluorouracil—colon cancer	0.000353	0.00119	CcSEcCtD
Cladribine—Alopecia—Capecitabine—colon cancer	0.000353	0.00119	CcSEcCtD
Cladribine—Pancytopenia—Methotrexate—colon cancer	0.000353	0.00119	CcSEcCtD
Cladribine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000351	0.00118	CcSEcCtD
Cladribine—Mental disorder—Capecitabine—colon cancer	0.00035	0.00118	CcSEcCtD
Cladribine—Feeling abnormal—Irinotecan—colon cancer	0.00035	0.00118	CcSEcCtD
Cladribine—Malnutrition—Capecitabine—colon cancer	0.000348	0.00117	CcSEcCtD
Cladribine—Erythema—Capecitabine—colon cancer	0.000348	0.00117	CcSEcCtD
Cladribine—Neutropenia—Methotrexate—colon cancer	0.000348	0.00117	CcSEcCtD
Cladribine—Pain—Fluorouracil—colon cancer	0.000348	0.00117	CcSEcCtD
Cladribine—Gastrointestinal pain—Irinotecan—colon cancer	0.000347	0.00117	CcSEcCtD
Cladribine—POLE—Synthesis of DNA—CDKN1A—colon cancer	0.000346	0.00178	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—BUB1B—colon cancer	0.000346	0.00178	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Methotrexate—colon cancer	0.000346	0.00116	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—colon cancer	0.000344	0.00116	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—colon cancer	0.000344	0.00116	CcSEcCtD
Cladribine—Flatulence—Capecitabine—colon cancer	0.000343	0.00115	CcSEcCtD
Cladribine—POLE2—Mitotic G1-G1/S phases—MYC—colon cancer	0.000339	0.00174	CbGpPWpGaD
Cladribine—Back pain—Capecitabine—colon cancer	0.000337	0.00113	CcSEcCtD
Cladribine—Body temperature increased—Irinotecan—colon cancer	0.000335	0.00113	CcSEcCtD
Cladribine—Abdominal pain—Irinotecan—colon cancer	0.000335	0.00113	CcSEcCtD
Cladribine—Feeling abnormal—Fluorouracil—colon cancer	0.000335	0.00113	CcSEcCtD
Cladribine—Pneumonia—Methotrexate—colon cancer	0.000333	0.00112	CcSEcCtD
Cladribine—Infestation—Methotrexate—colon cancer	0.000332	0.00112	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—colon cancer	0.000332	0.00112	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000329	0.00111	CcSEcCtD
Cladribine—Renal failure—Methotrexate—colon cancer	0.000326	0.0011	CcSEcCtD
Cladribine—RRM2—G1/S Transition—CDKN1A—colon cancer	0.000326	0.00167	CbGpPWpGaD
Cladribine—POLE—DNA Replication—CDKN1A—colon cancer	0.000325	0.00167	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MYC—colon cancer	0.000323	0.00166	CbGpPWpGaD
Cladribine—Ill-defined disorder—Capecitabine—colon cancer	0.000323	0.00109	CcSEcCtD
Cladribine—Urticaria—Fluorouracil—colon cancer	0.000323	0.00109	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000323	0.00166	CbGpPWpGaD
Cladribine—Conjunctivitis—Methotrexate—colon cancer	0.000322	0.00108	CcSEcCtD
Cladribine—Anaemia—Capecitabine—colon cancer	0.000322	0.00108	CcSEcCtD
Cladribine—Body temperature increased—Fluorouracil—colon cancer	0.000321	0.00108	CcSEcCtD
Cladribine—Hypersensitivity—Vincristine—colon cancer	0.000321	0.00108	CcSEcCtD
Cladribine—Malaise—Capecitabine—colon cancer	0.000314	0.00106	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—colon cancer	0.000314	0.00105	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—colon cancer	0.000313	0.00105	CcSEcCtD
Cladribine—POLE—G1/S Transition—CDKN1A—colon cancer	0.000313	0.00161	CbGpPWpGaD
Cladribine—Hypersensitivity—Irinotecan—colon cancer	0.000313	0.00105	CcSEcCtD
Cladribine—Asthenia—Vincristine—colon cancer	0.000313	0.00105	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—colon cancer	0.000311	0.0016	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MYC—colon cancer	0.000311	0.0016	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—TYMS—colon cancer	0.000308	0.00158	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—CDKN1A—colon cancer	0.000307	0.00158	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CHST5—colon cancer	0.000306	0.00157	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ODC1—colon cancer	0.000306	0.00157	CbGpPWpGaD
Cladribine—Asthenia—Irinotecan—colon cancer	0.000304	0.00102	CcSEcCtD
Cladribine—Cough—Capecitabine—colon cancer	0.000304	0.00102	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MYC—colon cancer	0.000302	0.00155	CbGpPWpGaD
Cladribine—Hypersensitivity—Fluorouracil—colon cancer	0.000299	0.00101	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—colon cancer	0.000299	0.00101	CcSEcCtD
Cladribine—Diarrhoea—Vincristine—colon cancer	0.000298	0.001	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—colon cancer	0.000298	0.001	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000297	0.00153	CbGpPWpGaD
Cladribine—Myalgia—Capecitabine—colon cancer	0.000296	0.000997	CcSEcCtD
Cladribine—Chest pain—Capecitabine—colon cancer	0.000296	0.000997	CcSEcCtD
Cladribine—Arthralgia—Capecitabine—colon cancer	0.000296	0.000997	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—colon cancer	0.000295	0.000994	CcSEcCtD
Cladribine—Anxiety—Capecitabine—colon cancer	0.000295	0.000993	CcSEcCtD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—EP300—colon cancer	0.000294	0.00151	CbGpPWpGaD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000294	0.00099	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—colon cancer	0.000294	0.000989	CcSEcCtD
Cladribine—POLE—S Phase—CCND1—colon cancer	0.000293	0.00151	CbGpPWpGaD
Cladribine—Discomfort—Capecitabine—colon cancer	0.000293	0.000985	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—EP300—colon cancer	0.000292	0.0015	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000292	0.0015	CbGpPWpGaD
Cladribine—Urethral disorder—Methotrexate—colon cancer	0.000292	0.000981	CcSEcCtD
Cladribine—Diarrhoea—Irinotecan—colon cancer	0.00029	0.000977	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000289	0.00149	CbGpPWpGaD
Cladribine—Dizziness—Vincristine—colon cancer	0.000288	0.000969	CcSEcCtD
Cladribine—Pruritus—Fluorouracil—colon cancer	0.000288	0.000967	CcSEcCtD
Cladribine—Confusional state—Capecitabine—colon cancer	0.000286	0.000964	CcSEcCtD
Cladribine—DCK—Metabolism—ODC1—colon cancer	0.000286	0.00147	CbGpPWpGaD
Cladribine—DCK—Metabolism—CHST5—colon cancer	0.000286	0.00147	CbGpPWpGaD
Cladribine—Oedema—Capecitabine—colon cancer	0.000284	0.000956	CcSEcCtD
Cladribine—POLE—S Phase—CDKN1A—colon cancer	0.000284	0.00146	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—CCND1—colon cancer	0.000284	0.00146	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MLH1—colon cancer	0.000283	0.00146	CbGpPWpGaD
Cladribine—Infection—Capecitabine—colon cancer	0.000282	0.000949	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—colon cancer	0.000281	0.000947	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000281	0.00145	CbGpPWpGaD
Cladribine—Dizziness—Irinotecan—colon cancer	0.000281	0.000944	CcSEcCtD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—colon cancer	0.000279	0.00143	CbGpPWpGaD
Cladribine—Nervous system disorder—Capecitabine—colon cancer	0.000279	0.000937	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—colon cancer	0.000278	0.000936	CcSEcCtD
Cladribine—Diarrhoea—Fluorouracil—colon cancer	0.000278	0.000936	CcSEcCtD
Cladribine—Thrombocytopenia—Capecitabine—colon cancer	0.000278	0.000936	CcSEcCtD
Cladribine—Tachycardia—Capecitabine—colon cancer	0.000277	0.000933	CcSEcCtD
Cladribine—Vomiting—Vincristine—colon cancer	0.000277	0.000932	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—colon cancer	0.000276	0.000929	CcSEcCtD
Cladribine—Skin disorder—Capecitabine—colon cancer	0.000276	0.000928	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	0.000276	0.00142	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TYMS—colon cancer	0.000275	0.00142	CbGpPWpGaD
Cladribine—Rash—Vincristine—colon cancer	0.000275	0.000924	CcSEcCtD
Cladribine—Hyperhidrosis—Capecitabine—colon cancer	0.000275	0.000924	CcSEcCtD
Cladribine—Dermatitis—Vincristine—colon cancer	0.000275	0.000924	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDKN1A—colon cancer	0.000275	0.00141	CbGpPWpGaD
Cladribine—Headache—Vincristine—colon cancer	0.000273	0.000918	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CCND1—colon cancer	0.000272	0.0014	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MLH1—colon cancer	0.000272	0.0014	CbGpPWpGaD
Cladribine—Anorexia—Capecitabine—colon cancer	0.000271	0.000911	CcSEcCtD
Cladribine—RRM2—G1/S Transition—MYC—colon cancer	0.00027	0.00139	CbGpPWpGaD
Cladribine—Angiopathy—Methotrexate—colon cancer	0.00027	0.000908	CcSEcCtD
Cladribine—Vomiting—Irinotecan—colon cancer	0.00027	0.000908	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—BUB1B—colon cancer	0.00027	0.00139	CbGpPWpGaD
Cladribine—Immune system disorder—Methotrexate—colon cancer	0.000269	0.000904	CcSEcCtD
Cladribine—Dizziness—Fluorouracil—colon cancer	0.000269	0.000904	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—colon cancer	0.000268	0.000902	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000268	0.00138	CbGpPWpGaD
Cladribine—Rash—Irinotecan—colon cancer	0.000268	0.0009	CcSEcCtD
Cladribine—Dermatitis—Irinotecan—colon cancer	0.000267	0.000899	CcSEcCtD
Cladribine—Chills—Methotrexate—colon cancer	0.000267	0.000898	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.000267	0.00137	CbGpPWpGaD
Cladribine—Headache—Irinotecan—colon cancer	0.000266	0.000894	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000266	0.00137	CbGpPWpGaD
Cladribine—Hypotension—Capecitabine—colon cancer	0.000265	0.000893	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CDKN1A—colon cancer	0.000264	0.00135	CbGpPWpGaD
Cladribine—Alopecia—Methotrexate—colon cancer	0.000263	0.000885	CcSEcCtD
Cladribine—NR5A1—Gene Expression—HNF4A—colon cancer	0.000262	0.00135	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000261	0.00134	CbGpPWpGaD
Cladribine—Mental disorder—Methotrexate—colon cancer	0.000261	0.000877	CcSEcCtD
Cladribine—POLE—G1/S Transition—MYC—colon cancer	0.000259	0.00133	CbGpPWpGaD
Cladribine—Erythema—Methotrexate—colon cancer	0.000259	0.000872	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—colon cancer	0.000259	0.000872	CcSEcCtD
Cladribine—Nausea—Vincristine—colon cancer	0.000259	0.000871	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—BUB1B—colon cancer	0.000259	0.00133	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000259	0.000871	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000259	0.00133	CbGpPWpGaD
Cladribine—Vomiting—Fluorouracil—colon cancer	0.000258	0.000869	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000257	0.00132	CbGpPWpGaD
Cladribine—Insomnia—Capecitabine—colon cancer	0.000257	0.000864	CcSEcCtD
Cladribine—Rash—Fluorouracil—colon cancer	0.000256	0.000862	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—colon cancer	0.000256	0.000861	CcSEcCtD
Cladribine—Paraesthesia—Capecitabine—colon cancer	0.000255	0.000858	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000255	0.00131	CbGpPWpGaD
Cladribine—Headache—Fluorouracil—colon cancer	0.000255	0.000857	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—MYC—colon cancer	0.000255	0.00131	CbGpPWpGaD
Cladribine—Dyspnoea—Capecitabine—colon cancer	0.000253	0.000852	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000253	0.0013	CbGpPWpGaD
Cladribine—Nausea—Irinotecan—colon cancer	0.000252	0.000848	CcSEcCtD
Cladribine—Back pain—Methotrexate—colon cancer	0.000251	0.000843	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000248	0.00128	CbGpPWpGaD
Cladribine—Decreased appetite—Capecitabine—colon cancer	0.000247	0.000831	CcSEcCtD
Cladribine—POLA1—Synthesis of DNA—CDKN1A—colon cancer	0.000247	0.00127	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—BUB1B—colon cancer	0.000247	0.00127	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000245	0.000825	CcSEcCtD
Cladribine—Fatigue—Capecitabine—colon cancer	0.000245	0.000824	CcSEcCtD
Cladribine—Pain—Capecitabine—colon cancer	0.000243	0.000817	CcSEcCtD
Cladribine—Constipation—Capecitabine—colon cancer	0.000243	0.000817	CcSEcCtD
Cladribine—Nausea—Fluorouracil—colon cancer	0.000241	0.000812	CcSEcCtD
Cladribine—RRM2—Cell Cycle—BUB1B—colon cancer	0.000241	0.00124	CbGpPWpGaD
Cladribine—Ill-defined disorder—Methotrexate—colon cancer	0.00024	0.000809	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.00024	0.00124	CbGpPWpGaD
Cladribine—Anaemia—Methotrexate—colon cancer	0.000239	0.000806	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—PPARG—colon cancer	0.000236	0.00121	CbGpPWpGaD
Cladribine—POLE—S Phase—MYC—colon cancer	0.000235	0.00121	CbGpPWpGaD
Cladribine—Feeling abnormal—Capecitabine—colon cancer	0.000234	0.000787	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000234	0.0012	CbGpPWpGaD
Cladribine—Malaise—Methotrexate—colon cancer	0.000234	0.000786	CcSEcCtD
Cladribine—Gastrointestinal pain—Capecitabine—colon cancer	0.000232	0.000781	CcSEcCtD
Cladribine—POLE—Cell Cycle—BUB1B—colon cancer	0.000231	0.00119	CbGpPWpGaD
Cladribine—POLA1—DNA Replication—CDKN1A—colon cancer	0.000231	0.00119	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—MYC—colon cancer	0.000228	0.00117	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000228	0.00117	CbGpPWpGaD
Cladribine—Cough—Methotrexate—colon cancer	0.000226	0.000761	CcSEcCtD
Cladribine—Urticaria—Capecitabine—colon cancer	0.000226	0.000759	CcSEcCtD
Cladribine—Abdominal pain—Capecitabine—colon cancer	0.000225	0.000755	CcSEcCtD
Cladribine—Body temperature increased—Capecitabine—colon cancer	0.000225	0.000755	CcSEcCtD
Cladribine—POLA1—G1/S Transition—CDKN1A—colon cancer	0.000223	0.00115	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PPARG—colon cancer	0.000222	0.00114	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MYC—colon cancer	0.000221	0.00114	CbGpPWpGaD
Cladribine—Chest pain—Methotrexate—colon cancer	0.000221	0.000742	CcSEcCtD
Cladribine—Myalgia—Methotrexate—colon cancer	0.000221	0.000742	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—colon cancer	0.000221	0.000742	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000219	0.000737	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—MYC—colon cancer	0.000218	0.00112	CbGpPWpGaD
Cladribine—Discomfort—Methotrexate—colon cancer	0.000218	0.000733	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	0.000216	0.00111	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000214	0.0011	CbGpPWpGaD
Cladribine—Confusional state—Methotrexate—colon cancer	0.000213	0.000717	CcSEcCtD
Cladribine—Infection—Methotrexate—colon cancer	0.00021	0.000707	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000209	0.00108	CbGpPWpGaD
Cladribine—Hypersensitivity—Capecitabine—colon cancer	0.000209	0.000704	CcSEcCtD
Cladribine—POLA1—S Phase—CCND1—colon cancer	0.000209	0.00108	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000209	0.00107	CbGpPWpGaD
Cladribine—Nervous system disorder—Methotrexate—colon cancer	0.000207	0.000698	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—colon cancer	0.000207	0.000696	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—TYMS—colon cancer	0.000207	0.00106	CbGpPWpGaD
Cladribine—Skin disorder—Methotrexate—colon cancer	0.000205	0.000691	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000205	0.00105	CbGpPWpGaD
Cladribine—Hyperhidrosis—Methotrexate—colon cancer	0.000204	0.000688	CcSEcCtD
Cladribine—Asthenia—Capecitabine—colon cancer	0.000204	0.000686	CcSEcCtD
Cladribine—POLA1—S Phase—CDKN1A—colon cancer	0.000202	0.00104	CbGpPWpGaD
Cladribine—Anorexia—Methotrexate—colon cancer	0.000202	0.000678	CcSEcCtD
Cladribine—Pruritus—Capecitabine—colon cancer	0.000201	0.000676	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—TYMS—colon cancer	0.000198	0.00102	CbGpPWpGaD
Cladribine—Hypotension—Methotrexate—colon cancer	0.000198	0.000665	CcSEcCtD
Cladribine—RRM2B—Metabolism—ABCB1—colon cancer	0.000197	0.00101	CbGpPWpGaD
Cladribine—Diarrhoea—Capecitabine—colon cancer	0.000194	0.000654	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CCND1—colon cancer	0.000194	0.000998	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MLH1—colon cancer	0.000194	0.000997	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—TYMS—colon cancer	0.000194	0.000996	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000193	0.000995	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000193	0.000648	CcSEcCtD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	0.000191	0.000985	CbGpPWpGaD
Cladribine—Insomnia—Methotrexate—colon cancer	0.000191	0.000643	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—colon cancer	0.00019	0.000639	CcSEcCtD
Cladribine—ABCG2—Metabolism—CA7—colon cancer	0.000189	0.000971	CbGpPWpGaD
Cladribine—Dyspnoea—Methotrexate—colon cancer	0.000189	0.000634	CcSEcCtD
Cladribine—Somnolence—Methotrexate—colon cancer	0.000188	0.000632	CcSEcCtD
Cladribine—Dizziness—Capecitabine—colon cancer	0.000188	0.000632	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDKN1A—colon cancer	0.000188	0.000965	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CA7—colon cancer	0.000187	0.000961	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TYMS—colon cancer	0.000185	0.00095	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—MYC—colon cancer	0.000185	0.00095	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—BUB1B—colon cancer	0.000184	0.000948	CbGpPWpGaD
Cladribine—Decreased appetite—Methotrexate—colon cancer	0.000184	0.000618	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000183	0.000614	CcSEcCtD
Cladribine—Fatigue—Methotrexate—colon cancer	0.000182	0.000613	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000182	0.000934	CbGpPWpGaD
Cladribine—Pain—Methotrexate—colon cancer	0.000181	0.000608	CcSEcCtD
Cladribine—Vomiting—Capecitabine—colon cancer	0.000181	0.000608	CcSEcCtD
Cladribine—Rash—Capecitabine—colon cancer	0.000179	0.000602	CcSEcCtD
Cladribine—Dermatitis—Capecitabine—colon cancer	0.000179	0.000602	CcSEcCtD
Cladribine—Headache—Capecitabine—colon cancer	0.000178	0.000599	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000178	0.000914	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TYMS—colon cancer	0.000177	0.000912	CbGpPWpGaD
Cladribine—Feeling abnormal—Methotrexate—colon cancer	0.000174	0.000586	CcSEcCtD
Cladribine—SLC22A1—Metabolism—CA7—colon cancer	0.000174	0.000896	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000173	0.00089	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Methotrexate—colon cancer	0.000173	0.000582	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000172	0.000884	CbGpPWpGaD
Cladribine—PNP—Metabolism—ABCB1—colon cancer	0.000171	0.000879	CbGpPWpGaD
Cladribine—Nausea—Capecitabine—colon cancer	0.000169	0.000568	CcSEcCtD
Cladribine—Urticaria—Methotrexate—colon cancer	0.000168	0.000565	CcSEcCtD
Cladribine—PNP—Metabolism—TYMS—colon cancer	0.000168	0.000863	CbGpPWpGaD
Cladribine—POLA1—S Phase—MYC—colon cancer	0.000168	0.000862	CbGpPWpGaD
Cladribine—Body temperature increased—Methotrexate—colon cancer	0.000167	0.000562	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—colon cancer	0.000167	0.000562	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BUB1B—colon cancer	0.000165	0.000848	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000164	0.000843	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000163	0.000837	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CTNNB1—colon cancer	0.000156	0.000804	CbGpPWpGaD
Cladribine—Hypersensitivity—Methotrexate—colon cancer	0.000156	0.000524	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—colon cancer	0.000156	0.0008	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—colon cancer	0.000155	0.000797	CbGpPWpGaD
Cladribine—Asthenia—Methotrexate—colon cancer	0.000152	0.00051	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000151	0.000777	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN1A—colon cancer	0.00015	0.000771	CbGpPWpGaD
Cladribine—Pruritus—Methotrexate—colon cancer	0.00015	0.000503	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000147	0.000756	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000146	0.000749	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EP300—colon cancer	0.000145	0.000748	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000145	0.000747	CbGpPWpGaD
Cladribine—Diarrhoea—Methotrexate—colon cancer	0.000145	0.000487	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—EP300—colon cancer	0.000143	0.000734	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000142	0.000731	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—SRC—colon cancer	0.000141	0.000727	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TYMS—colon cancer	0.000141	0.000727	CbGpPWpGaD
Cladribine—Dizziness—Methotrexate—colon cancer	0.00014	0.00047	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCND1—colon cancer	0.000139	0.000713	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—VEGFA—colon cancer	0.000138	0.000708	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PPARG—colon cancer	0.000137	0.000705	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—NRAS—colon cancer	0.000136	0.000699	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000135	0.000696	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—colon cancer	0.000135	0.000692	CbGpPWpGaD
Cladribine—Vomiting—Methotrexate—colon cancer	0.000134	0.000452	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDKN1A—colon cancer	0.000134	0.000689	CbGpPWpGaD
Cladribine—Rash—Methotrexate—colon cancer	0.000133	0.000449	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—colon cancer	0.000133	0.000448	CcSEcCtD
Cladribine—Headache—Methotrexate—colon cancer	0.000132	0.000446	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000132	0.000677	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000128	0.000659	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—EP300—colon cancer	0.000128	0.000656	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TYMS—colon cancer	0.000126	0.00065	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TGFB1—colon cancer	0.000126	0.00065	CbGpPWpGaD
Cladribine—Nausea—Methotrexate—colon cancer	0.000126	0.000423	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—colon cancer	0.000124	0.000639	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—colon cancer	0.000124	0.000637	CbGpPWpGaD
Cladribine—PNP—Metabolism—PPARG—colon cancer	0.000119	0.000611	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000118	0.000606	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000118	0.000605	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—colon cancer	0.000117	0.000602	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000115	0.000593	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ODC1—colon cancer	0.000114	0.000588	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CHST5—colon cancer	0.000114	0.000588	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PPARG—colon cancer	0.000114	0.000584	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ODC1—colon cancer	0.000113	0.000582	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CHST5—colon cancer	0.000113	0.000582	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—colon cancer	0.000111	0.000572	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000109	0.00056	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—colon cancer	0.000108	0.000555	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CHST5—colon cancer	0.000106	0.000543	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ODC1—colon cancer	0.000106	0.000543	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BRAF—colon cancer	0.000105	0.00054	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	0.000105	0.000538	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—colon cancer	0.000104	0.000535	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN1A—colon cancer	0.000101	0.000518	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.0001	0.000515	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—colon cancer	9.99e-05	0.000514	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—colon cancer	9.95e-05	0.000512	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ABCB1—colon cancer	9.82e-05	0.000505	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BRAF—colon cancer	9.79e-05	0.000504	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	9.69e-05	0.000498	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN1A—colon cancer	9.66e-05	0.000497	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TYMS—colon cancer	9.64e-05	0.000496	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—EP300—colon cancer	9.58e-05	0.000493	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—colon cancer	9.36e-05	0.000481	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—colon cancer	9.31e-05	0.000478	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—EP300—colon cancer	9.2e-05	0.000473	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—colon cancer	9.13e-05	0.000469	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN1A—colon cancer	9e-05	0.000463	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—EP300—colon cancer	8.97e-05	0.000461	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—colon cancer	8.93e-05	0.000459	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—AKT1—colon cancer	8.79e-05	0.000452	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN1A—colon cancer	8.64e-05	0.000444	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—EP300—colon cancer	8.57e-05	0.00044	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—colon cancer	8.35e-05	0.000429	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—EP300—colon cancer	8.22e-05	0.000423	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	8.18e-05	0.000421	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—colon cancer	8.08e-05	0.000416	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—colon cancer	8.05e-05	0.000414	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—colon cancer	8.01e-05	0.000412	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—colon cancer	7.94e-05	0.000408	CbGpPWpGaD
Cladribine—PNP—Metabolism—EP300—colon cancer	7.78e-05	0.0004	CbGpPWpGaD
Cladribine—DCK—Metabolism—ABCB1—colon cancer	7.56e-05	0.000388	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—colon cancer	7.5e-05	0.000386	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—colon cancer	7.46e-05	0.000384	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—colon cancer	7.42e-05	0.000382	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—colon cancer	7.16e-05	0.000368	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—colon cancer	7.12e-05	0.000366	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1A—colon cancer	6.89e-05	0.000354	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPARG—colon cancer	6.83e-05	0.000351	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—colon cancer	6.64e-05	0.000341	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—EP300—colon cancer	6.55e-05	0.000337	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—colon cancer	6.48e-05	0.000333	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	6.46e-05	0.000332	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—colon cancer	6.39e-05	0.000328	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—colon cancer	6.36e-05	0.000327	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1A—colon cancer	6.16e-05	0.000317	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—colon cancer	6.13e-05	0.000315	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—colon cancer	5.95e-05	0.000306	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—colon cancer	5.88e-05	0.000303	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—EP300—colon cancer	5.86e-05	0.000301	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—colon cancer	5.76e-05	0.000296	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—colon cancer	5.71e-05	0.000294	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPARG—colon cancer	5.62e-05	0.000289	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—colon cancer	5.42e-05	0.000279	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—colon cancer	5.37e-05	0.000276	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPARG—colon cancer	5.26e-05	0.00027	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—colon cancer	5.11e-05	0.000262	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—colon cancer	4.83e-05	0.000248	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—colon cancer	4.7e-05	0.000242	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—colon cancer	4.5e-05	0.000232	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—colon cancer	4.49e-05	0.000231	CbGpPWpGaD
Cladribine—RRM1—Metabolism—EP300—colon cancer	4.47e-05	0.00023	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—colon cancer	4.42e-05	0.000228	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—colon cancer	4.19e-05	0.000216	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—colon cancer	4.13e-05	0.000213	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—colon cancer	3.7e-05	0.00019	CbGpPWpGaD
Cladribine—RRM2—Metabolism—EP300—colon cancer	3.68e-05	0.000189	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—colon cancer	3.45e-05	0.000177	CbGpPWpGaD
Cladribine—DCK—Metabolism—EP300—colon cancer	3.44e-05	0.000177	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—colon cancer	3.31e-05	0.00017	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—colon cancer	3.02e-05	0.000155	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—colon cancer	2.99e-05	0.000154	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—colon cancer	2.97e-05	0.000153	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—colon cancer	2.94e-05	0.000151	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—colon cancer	2.79e-05	0.000143	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—colon cancer	2.74e-05	0.000141	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—colon cancer	2.72e-05	0.00014	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—colon cancer	2.7e-05	0.000139	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—colon cancer	2.54e-05	0.000131	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—colon cancer	2.22e-05	0.000114	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPARG—colon cancer	2.1e-05	0.000108	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARG—colon cancer	2.08e-05	0.000107	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—colon cancer	2.08e-05	0.000107	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARG—colon cancer	1.94e-05	9.98e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—colon cancer	1.65e-05	8.51e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—colon cancer	1.64e-05	8.42e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—colon cancer	1.53e-05	7.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—EP300—colon cancer	1.38e-05	7.08e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—EP300—colon cancer	1.36e-05	7e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—EP300—colon cancer	1.27e-05	6.53e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—colon cancer	1.02e-05	5.23e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—colon cancer	1.01e-05	5.18e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—colon cancer	9.39e-06	4.83e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—colon cancer	8.32e-06	4.28e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—colon cancer	8.23e-06	4.23e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—colon cancer	7.67e-06	3.94e-05	CbGpPWpGaD
